None listed
Conditions
Brief summary
The purpose of this study is to determine if integrated oncogeriatric care improves outcome in older patients who are receiving chemotherapy for cancer. Who is it for? You may be eligible to join this study if you are aged 70 years or above, have been diagnosed with cancer and are about to start chemotherapy (this includes cytotoxic chemotherapy, targeted therapy or immunotherapy). Study details. Participants in this study will be randomly (by chance) allocated to one of two treatment groups. Participants in one group will receive integrated oncogeriatric care. In addition to seeing their oncology doctors, participants receiving integrated oncogeriatric care will also have a comprehensive assessment and management by a geriatrician to identify problems early on and help co-ordinate care to support patients, their carers and their families better. Participants in the other group will receive standard oncology care and continue to see their oncology doctors for treatment of their cancer. Participants will be regularly assessed over 24 weeks by questionnaires to determine whether integrated oncogeriatric care improves quality of life, function, mood, nutrition, chemotherapy delivery, healthcare utilisation and healthcare costs.
Interventions
Integrated oncogeriatric care
Integrated oncogeriatric care consists of comprehensive geriatric assessment and management, integrated with standard oncology care. In addition to seeing their oncologists, participants receiving integrated oncogeriatric care will have a comprehensive assessment and management by a consultant physician in geriatric medicine within 3 weeks from randomisation, followed by reviews at approximately 12 weeks and 24 weeks from randomisation. After 24 weeks from randomis
Integrated oncogeriatric care Integrated oncogeriatric care consists of comprehensive geriatric assessment and management, integrated with standard oncology care. In addition to seeing their oncologists, participants receiving integrated oncogeriatric care will have a comprehensive assessment and management by a consultant physician in geriatric medicine within 3 weeks from randomisation, followed by reviews at approximately 12 weeks and 24 weeks from randomisation. After 24 weeks from randomisation, participants in the intervention arm may continue to receive integrated oncogeriatric care but will not be required to complete further study assessments.
Sponsors
Eastern Health
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged 70 years or older 2. Pathologically confirmed solid organ cancer or diffuse large B-cell lymphoma 3. Planned for cytotoxic chemotherapy, targeted therapy or immunotherapy 4. Able to effectively understand the language of the quality of life questionnaires in one of the validated languages for the questionnaires 5. Able to give written informed consent before randomisation according to local, national and international regulations
Exclusion criteria
1. Have received cytotoxic chemotherapy, targeted therapy or immunotherapy within 3 months prior to enrolment 2. Unable to self-complete the health-related quality of life questionnaires 3. Any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol 4. Prior enrolment in this study
Outcome results
None listed